EcoDrugPlus

Alpha Glucosidase

Ensembl ID : ENSSTUG00000043789
Gene Symbol: GAA
3 Cross references
227 Possible Orthologues:

Alpha-1a Adrenergic Receptor-Like

Ensembl ID : ENSSTUG00000023813
Gene Symbol: LOC115164571
3 Cross references
196 Possible Orthologues:

Alpha-1a Adrenergic Receptor-Like

Ensembl ID : ENSSTUG00000012377
Gene Symbol: LOC115205430
3 Cross references
185 Possible Orthologues:

Alpha-1a Adrenergic Receptor-Like

Ensembl ID : ENSSTUG00000005557
Gene Symbol: LOC115200073
3 Cross references
196 Possible Orthologues:

Alpha-2a Adrenergic Receptor-Like

Ensembl ID : ENSSTUG00000036789
Gene Symbol: LOC115178424
3 Cross references
173 Possible Orthologues:

Alpha-2a Adrenergic Receptor-Like

Ensembl ID : ENSSTUG00000045983
Gene Symbol: LOC115147380
3 Cross references
168 Possible Orthologues:

Alpha-2b Adrenergic Receptor-Like

Ensembl ID : ENSSTUG00000043601
Gene Symbol: LOC115160292
3 Cross references
143 Possible Orthologues:

Alpha-2b Adrenergic Receptor-Like

Ensembl ID : ENSSTUG00000034548
Gene Symbol: LOC115164332
3 Cross references
168 Possible Orthologues:

Alpha-2b Adrenergic Receptor-Like

Ensembl ID : ENSSTUG00000049186
Gene Symbol: LOC115200319
3 Cross references
169 Possible Orthologues:

Alpha-2b Adrenergic Receptor-Like

Ensembl ID : ENSSTUG00000005098
Gene Symbol: LOC115203905
3 Cross references
145 Possible Orthologues:

Alpha-2c Adrenergic Receptor-Like

Ensembl ID : ENSSTUG00000023005
Gene Symbol: LOC115181971
3 Cross references
160 Possible Orthologues:

Amiloride-Sensitive Amine Oxidase [Copper-Containing]-Like

Ensembl ID : ENSSTUG00000002780
Gene Symbol: LOC115195631
3 Cross references
225 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).